| 2026-07-30 | Deck | Earnings presentation · Q2 2026 · Jul 2026 |
| 2026-07-30 | Press release | Guardant Health to Report Second Quarter 2026 Financial Results on |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| Transcript | Q2 FY26 earnings call transcript |
| 2026-07-29 | Press release | Guardant Health to Participate in Upcoming Investor Conferences |
| 2026-07-28 | Press release | Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who |
| 2026-07-21 | Press release | Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-01 | Press release | UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening |
| 2026-06-18 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-02 | Deck | Investor presentation · Jun 2026 |
| 2026-05-07 | Press release | Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance |
| 2026-05-07 | Press release | Guardant Health to Report First Quarter 2026 Financial Results on |
| 2026-05-07 | Deck | Presentation of Q1 2026 |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-28 | Proxy | Definitive proxy statement |
| 2026-04-27 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-21 | Press release | Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Transcript | Q1 FY26 earnings call transcript |
| 2026-03-30 | Press release | Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan |
| 2026-03-18 | Press release | Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 |
| 2026-03-16 | Press release | Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership |
| 2026-03-13 | Press release | New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare |
| 2026-03-10 | Press release | Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics |
| 2026-03-04 | Press release | Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America |
| 2026-03-03 | Press release | Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened |
| 2026-02-23 | Press release | Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-21 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-19 | Press release | Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook |
| 2026-02-19 | Deck | Guardant Health Q4 and Full Year 2025 Earnings Call |
| 2026-02-19 | Press release | Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on |
| 2026-02-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-19 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-03 | Press release | Guardant Health to Participate in Upcoming Investor Conferences |
| 2026-02-02 | Press release | Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions |
| 2026-01-22 | Press release | Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer |
| 2026-01-19 | Press release | Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform |
| 2026-01-12 | Deck | Investor presentation · Jan 2026 |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |